
CB-839
CAS No. 1439399-58-2
CB-839( CB839 | CB 839 | Telaglenastat )
Catalog No. M11862 CAS No. 1439399-58-2
CB-839 (Telaglenastat) is a potent, selective, and orally bioavailable inhibitor of glutaminase with IC50 of 28 and 23 nM for glutaminase in kidney and brain (GAC and KGA).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 42 | In Stock |
![]() ![]() |
10MG | 65 | In Stock |
![]() ![]() |
25MG | 115 | In Stock |
![]() ![]() |
50MG | 200 | In Stock |
![]() ![]() |
100MG | 332 | In Stock |
![]() ![]() |
500MG | 782 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameCB-839
-
NoteResearch use only, not for human use.
-
Brief DescriptionCB-839 (Telaglenastat) is a potent, selective, and orally bioavailable inhibitor of glutaminase with IC50 of 28 and 23 nM for glutaminase in kidney and brain (GAC and KGA).
-
DescriptionCB-839 (Telaglenastat) is a potent, selective, and orally bioavailable inhibitor of glutaminase with IC50 of 28 and 23 nM for glutaminase in kidney and brain (GAC and KGA), but not the liver form of glutaminase (GLS2, IC50>1 uM); demonstrates antiproliferative activity in triple-negative breast cancer (TNBC) cell line HCC-1806 and MDA-MB-231 with IC50 of 20-55 nM, decreases glutamine consumption, glutamate production, oxygen consumption, and the steady-state levels of glutathione and several tricarboxylic acid cycle intermediates; exhibits vivo efficacy in breast cancer xenograft models, both as a single agent and in combination with paclitaxel. Kidney Cancer Phase 2 Clinical(In Vitro):Telaglenastat (CB-839) (0.1-1000 nM; 72 hours) has antiproliferative activity in HCC1806 and MDA-MB-231 cells with IC50s of 49 nM and 26 nM, respectively.Telaglenastat (CB-839) (1 μM; 72 hours) activates caspase 3/7 and induces apoptosis in MDA-MB-231 and HCC1806 cells.(In Vivo):Telaglenastat (CB-839) (200 mg/kg; p.o.; twice daily for 28 days) has antitumor activity in xenograft models of TNBC.
-
In VitroTelaglenastat (CB-839) (0.1-1000 nM; 72 hours) has antiproliferative activity in HCC1806 and MDA-MB-231 cells with IC50s of 49 nM and 26 nM, respectively.Telaglenastat (CB-839) (1 μM; 72 hours) activates caspase 3/7 and induces apoptosis in MDA-MB-231 and HCC1806 cells. Cell Proliferation Assay Cell Line:HCC1806, MDA-MB-231 cells Concentration:0.1, 1, 10, 100, 1000 nM Incubation Time:72 hours Result:Has a potent effect on the proliferation of the two TNBC cell lines (IC50 of 49 nM and 26 nM for HCC1806 and MDA-MB-231 cells).Apoptosis AnalysisCell Line:MDA-MB-231, HCC1806 cells Concentration:1 μM Incubation Time:72 hours Result:Caspase 3/7 activation.
-
In VivoTelaglenastat (CB-839) (200 mg/kg; p.o.; twice daily for 28 days) has antitumor activity in xenograft models of TNBC. Animal Model:Female nu/nu mice with age 4–6 weeks (TNBC patient-derived xenograft model)Dosage:200 mg/kg Administration:Oral administration; twice daily for 28 days Result:Suppressed tumor growth by 61% relative to vehicle control at the end of study.
-
SynonymsCB839 | CB 839 | Telaglenastat
-
PathwayOthers
-
TargetOther Targets
-
RecptorGLUT
-
Research AreaCancer
-
IndicationKidney Cancer
Chemical Information
-
CAS Number1439399-58-2
-
Formula Weight571.5741
-
Molecular FormulaC26H24F3N7O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 30 mg/mL
-
SMILESO=C(NC1=CC=C(CCCCC2=NN=C(NC(CC3=NC=CC=C3)=O)S2)N=N1)CC4=CC(OC(F)(F)F)=CC=C4
-
Chemical Name2-Pyridineacetamide, N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Gross MI, et al. Mol Cancer Ther. 2014 Apr;13(4):890-901.
2. Jacque N, et al. Blood. 2015 Sep 10;126(11):1346-56.
3. Chakrabarti G, et al. Cancer Metab. 2015 Oct 12;3:12.
4. Zimmermann SC, et al. ACS Med Chem Lett. 2016 Mar 13;7(5):520-4.
molnova catalog



related products
-
Pamoic acid disodium
Pamoic acid disodium is a GPR35 agonist.
-
2-Hydroxy-3-methoxyb...
2-Hydroxy-3-methoxybenzoic acid glucose ester shows a potent antagonistic activity against platelet activating factor (PAF), it can prevent the mice from the PAF-induced death at a dose of 300 micrograms/mouse.
-
Pitavastatin lactone
Pitavastatin lactone is a major Pitavastatin metabolite in humans. Pitavastatin is a potent competitive inhibitor of HMG-CoA reductase little metabolized in hepatic microsomes.